Hematological immune-related adverse events associated with checkpoint inhibitors.
Recognition and management guidance for hidden blood-related side effects helps oncologists better protect patients receiving checkpoint inhibitor immunotherapy.
This review consolidates evidence on hematological irAEs from checkpoint inhibitors, encompassing autoimmune cytopenias, aplastic anemia, and hemophagocytic lymphohistiocytosis in cancer patients receiving ICI therapy. It directly intersects hematology and immunotherapy and offers clinicians management guidance for under-recognized toxicities.
What the study was
- Study design
- Systematic review
- Population
- Cancer patients receiving checkpoint inhibitor therapy with hematological irAEs
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Cancer Treatment Reviews
Why it surfaced
Directly relevant to hematology + immunotherapy intersection; systematic review provides high utility for clinical management; Cancer Treatment Reviews is high-impact subspecialty journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.